Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2019

View Archived Issues

LIDDS begins phase I study of intratumoral NanoZolid combined with docetaxel for solid tumors

Identification of a novel immunotherapy target to treat myeloid blood cancers

Analysis identifies key bacterial virulence gene

DermBiont initiates phase II study of DBI-001 for the treatment of athlete's foot

Veverimer phase III results for metabolic acidosis associated with chronic kidney disease

ABBV-151 enters first-in-human study

Scholar Rock names TGF-beta1 activation inhibitor for further development

Targeting AhR for treating age-related macular degeneration proven useful

Bayer presents CHICO phase III results for nifurtimox in pediatric Chagas disease

FP-101 relieves hot flashes in menopausal women and women taking tamoxifen

ImmunogenX initiates phase II study of latiglutenase for celiac disease

Fujian Institute of Research on the Structure of Matter presents interferon modulators

Jiangsu Chia Tai Tianqing Pharmaceutical Group and others patent TRK inhibitors

Asceneuron discovers N-acetyl-beta-D-glucosaminidase inhibitors

Acesion Pharma identifies new SK (Ca) 2.3 channel blockers

New PIK3C3 and authophagy inhibitors synthesized at Sprint Bioscience

Phase I/II study planned for ACT-107 after first-in-human results show safety

Sutro initiates phase I study of STRO-002 in ovarian and endometrial cancers

Spectrum withdraws BLA for Rolontis with plans to resubmit

BCL9 targeting impacts intestinal neoplasia pathogenesis

Recreating lineage-specific cardiac cells from iPSCs

Antibodies to mosquito saliva offer Zika protection

Protein kinase C inhibitor LXS-196 studied in uveal melanoma patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...